allopurinol / Generic mfg. - LARVOL DELTA

CASE SERIES OF COMPLEX PERIANAL FISTULAS WITHOUT LUMINAL CROHN'S DISEASE AT TERTIARY CENTER. (CCCongress 2026) - "One patient received combination therapy with infliximab and azathioprine 150 mg daily and allopurinol 300 mg. One patient was on therapy with guselkumab and upadacitinib (45 mg daily), with promising fistula healing... The cases described present the multimodal importance of perianal Crohn’s involving immunomodulators and surgical intervention in patients without luminal inflammation. This patient cohort includes patients who are currently receiving induction doses of infliximab to an established patient on infliximab 10 mg/kg. Anti-TNF therapy was used as the baseline therapy in our patients."

Clinical • Constipation • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Wer bekommt die gefährliche Allopurinol-Nebenwirkung? (PubMed, MMW Fortschr Med) - No abstract available

Journal

Development of a non-genetic risk prediction model for allopurinol-induced severe cutaneous adverse drug reactions: a multicenter retrospective observational study. (PubMed, Clin Rheumatol) - "The developed non-genetic prediction model demonstrated good discriminative performance. This prediction score could assist physicians' decisions in prescribing allopurinol in the areas where HLA-B*58:01 is limited or unavailable. External validation in future studies is warranted. Key Points • A non-genetic risk prediction model for allopurinol-induced Severe Cutaneous Adverse Drug Reactions, NoG-ASCAR Score, is simple to access and apply in real clinical practice. • The performance of the area under the receiver operating characteristic curve for predicting SCAR of each model was good and had an impact on clinical utility. • It could provide confidence to physicians in prescribing allopurinol in the situation where HLA-B*58:01 assessment is limited or unavailable. • The NoG-ASCAR Score should be considered by policymakers when conducting cost-effectiveness analysis prior to recommending routine HLA-B*58:01 testing before allopurinol initiation."

Adverse drug reaction • Journal • Observational data • Retrospective data • Immunology • HLA-B

New α-glucosidase inhibitory isoflavone derivatives from the leaves of Placolobium vietnamense. (PubMed, J Asian Nat Prod Res) - "Among them, compound 1 exhibited the strongest α-glucosidase inhibition (IC50 21.6 ± 1.04 µM), which was markedly more potent than the positive control, acarbose (IC50 156.2 ± 5.43 µM). In addition, compound 1 showed the highest xanthine oxidase inhibitory activity (IC50 32.8 ± 0.08 µM), although it remained considerably less potent than the positive control, allopurinol (IC50 2.45 ± 0.01 µM)."

Journal

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation (ASH 2023) - P2 | "For pts who remained high TLS risk at the time of V initiation, TLS ppx throughout dose escalation included allopurinol to start at least 3 days prior to V initiation, sevelamer to start 12 hours prior to V initiation, and oral intake of ≥2 L water daily. On days of dose escalation, ppx additionally included kayexalate, rasburicase, and IV normal saline on D1 and D2 of each dose escalation... A single cycle of O effectively reduced TLS risk prior to introduction of V escalation with most pts achieving low or med TLS risk by C1D22. Notably, 90% of pts with high pre-tx TLS risk converted to low or med risk following C1 of O allowing for outpatient V escalation per FDA label. Further, we demonstrate that V dose escalation can be safely accomplished in the outpatient setting with close monitoring regardless of TLS risk."

Clinical • Minimal residual disease • P2 data • Residual disease • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma (ASH 2024) - P2 | "However, PFS was inferior for patients (pts) treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 days) compared with other regimens, supporting intensification of therapy beyond R-CHOP-21 in this entity. (eg. Allopurinol, co-trimoxazole). Study enrolment, safety and efficacy analyses are ongoing."

Clinical • P2 data • Alopecia • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • PD-L2

Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. (PubMed, Med Sci (Basel)) - " SGLT2 inhibitors achieved comparable sUA reduction to allopurinol by 36 months while preserving eGFR. Allopurinol was associated with higher mortality and hospitalization rates; SGLT2 inhibitor therapy was associated with favorable multidomain outcomes, but strategies to address adverse effects are needed to enhance adherence."

Clinical • Journal • Retrospective data • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial (ASH 2022) - "Background Venetoclax (VEN) plus azacitidine has an established role in the management of older patients (pts) with AML (DiNardo, NEJM 2020)...We now present an updated analysis of this trial (with >3 years median follow-up), reporting on the optimal dose of VEN with chemotherapy, with and without posaconazole (POSA), the deliverability of consolidation therapy, characteristics of treatment failure and observation of substantial treatment-free remission in subsets of pts using this time-limited, short-course regimen...For induction, VEN was administered over 14 days, commencing with a 7-day pre-chemo dose ramp-up, followed by a 7-day overlap with 5+2 chemotherapy (cytarabine 100mg/m2/d IVI d1-5 and idarubicin 12mg/m2 IV d2-3)...Induction with VEN-POSA (n=18) was also well tolerated (30-day mortality 0%) with 3 DLTs observed: 2 hematologic (1 in each cohort) and 1 due to pulmonary infiltrates occurring on d2 induction (suspected to be allopurinol..."

Clinical • Acute Myelogenous Leukemia • Hematological Disorders • Immunology • FLT3 • IDH2 • KIT • NPM1

Assessing willingness to pay for HLA-B*58:01 genetic testing before allopurinol initiation and its potential impact on future health policy, Thailand. (PubMed, Sci Rep) - "WTP for febuxostat, sulfinpyrazone, and benzbromarone was 68.00%, 67.60%, and 71.60%, respectively. Overall, most participants were willing to pay THB 500 (USD 14.36) for the genetic testing. The study provides insights for policymakers in pricing the genetic testing and ULT coverage in Thailand."

Journal • Gout • Inflammatory Arthritis • Rheumatology • HLA-B

Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies. (PubMed, Diabetes Care) - "For patients with gout and type 2 diabetes, SGLT2is may reduce gout-related medication use, which could, in turn, reduce exposure to the harmful cardiovascular-kidney-metabolic effects of NSAIDs and glucocorticoids in this high-risk population."

Journal • Cardiovascular • Diabetes • Gout • Inflammatory Arthritis • Metabolic Disorders • Rheumatology • Type 2 Diabetes Mellitus

The role of allopurinol in metabolic dysfunction-associated steatotic liver disease: A randomized clinical trial. (PubMed, Arab J Gastroenterol) - "Allopurinol administration in MASLD patients improved ultrasonographic grading and liver enzymes from baseline. However, the comparison with the control group did not support the beneficial effects."

Clinical • Journal • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study. (PubMed, Front Med (Lausanne)) - "Combining SGLT2 inhibitors and ULT (mainly allopurinol) in people with gout achieved significant SU reductions and helped achieve treatment goals. These results, alongside lower diuretic use and possibly lower allopurinol dose requirements, point towards an interesting management approach for gout."

Journal • Observational data • Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Gout • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology

HLA-SCREEN: HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness (clinicaltrials.gov) - P4 | N=228 | Not yet recruiting | Sponsor: Haiphong University of Medicine and Pharmacy

HEOR • New P4 trial • Gout • Immunology • Inflammatory Arthritis • Rheumatology • HLA-B

β-Carboline alkaloid harmaline alleviates hyperuricemia-mediated renal inflammation by suppressing oxidative stress. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Harmaline (2.5 and 5 mg/kg, i.p.) and allopurinol (10 mg/kg, i.p.) were administered 1-h after potassium oxonate treatment...Notably, the higher dose of harmaline exhibited the prominent effect. Overall, the results suggest that harmaline, particularly at 5 mg/kg, effectively alleviates potassium oxonate-induced hyperuricemia and renal dysfunction in mice."

Journal • Cardiovascular • Chronic Kidney Disease • Gout • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Rheumatology • IL10 • IL6 • TNFA

Drug-Drug Interaction Study of ABP-671 in Gout Patients (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Atom Therapeutics Co., Ltd

New P1 trial • Gout • Inflammatory Arthritis • Rheumatology

Dual-drug nanocarriers for gout therapy: targeted co-delivery of anti-inflammatory and urate-lowering agents: a review. (PubMed, EXCLI J) - "Current pharmacologic monotherapies such as xanthine oxidase inhibitors, uricosurics, NSAIDs, corticosteroids, and colchicine are often limited by inadequate dual-action efficacy, suboptimal bioavailability, and systemic side effects...Co-delivery of agents such as allopurinol or febuxostat with NSAIDs or corticosteroids may reduce pill burden, improve therapeutic synergy, and enhance patient adherence...See also the graphical abstract(Fig. 1)."

Journal • Review • Gout • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology

Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome in a patient with previous nephrectomy: a case report. (PubMed, J Med Case Rep) - "This case highlights the importance of a clear medication history when assessing a patient with cutaneous and systemic symptoms. It highlights that drug reaction with eosinophilia and systemic symptoms is a rare, but an important differential to consider, particularly in patients with underlying kidney dysfunction, even in those without intrinsic kidney disease."

Journal • Acute Kidney Injury • Eosinophilia • Gout • Hematological Disorders • Hypotension • Immunology • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • Vasculitis

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: VA Office of Research and Development | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Drug rash with eosinophilia and systemic symptoms: descriptive analysis of pharmacovigilance. (PubMed, Eur J Hosp Pharm) - "DRESS remains a severe adverse drug reaction. Early recognition and continuous pharmacovigilance are essential to reduce associated morbidity and mortality."

Adverse events • Journal • Dermatology • Eosinophilia

Trimetazidine and allopurinol for the prevention of Contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial. (PubMed, Eur J Clin Pharmacol) - "The TMZ-allopurinol combination showed a favorable but non-significant trend toward reducing CA-AKI, while ACEF and Mehran scores demonstrated limited predictive value. Improved risk-stratification tools and larger studies in higher-risk patients are needed. SGLT2 and DPP-4 inhibitors showed smaller creatinine increases, suggesting possible nephroprotection, but this remains exploratory."

Journal • Acute Kidney Injury • Nephrology • Renal Disease

An Unusual Presentation of Acquired Perforating Dermatosis Confined to the Scalp. (PubMed, Cureus) - "Histopathological examination confirmed the diagnosis, revealing transepidermal elimination of degenerated collagen bundles. Sequential treatment with oral clindamycin followed by allopurinol resulted in marked clinical improvement and complete resolution within one month of therapy."

Journal • Chronic Kidney Disease • Dermatology • Diabetes • Metabolic Disorders • Nephrology • Pruritus • Renal Disease • Type 1 Diabetes Mellitus

Ivemark syndrome in an adult with complete atrioventricular septal defect and a single ventricle with L-transposition of the great arteries: a case report. (PubMed, J Med Case Rep) - "This case highlights the rare adult presentation of Ivemark syndrome. Long-term survival is exceptionally rare and depends on balanced hemodynamics, comprehensive evaluation, and individualized multidisciplinary care."

Journal • Cardiovascular • Fatigue • Palliative care • Pulmonary Disease

The impact of anti-gout medications on eight cardiovascular diseases: a Mendelian randomized study. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

Allopurinol Use Is Associated with Decreased Incidence of Hepatic Decompensation and Overall Mortality among Individuals with Cirrhosis: A Propensity-Matched Cohort Study. (PubMed, GE Port J Gastroenterol) - "In a propensity score-matched analysis of a large national database, individuals with cirrhosis and allopurinol use had significantly lower risk of hepatic decompensation and overall mortality. These findings suggest that allopurinol may play a potential role in managing cirrhosis, and randomized clinical trials are needed to confirm these findings."

Clinical • Journal • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Nephrology • Oncology • Renal Disease • Solid Tumor

Serendipitous Symptom Control: Allopurinol for Spasticity in a Case of SPG4-Linked Hereditary Spastic Paraplegia-A Case Report. (PubMed, Clin Case Rep) - "In a patient with genetically confirmed SPG4-linked hereditary spastic paraplegia, initiation of allopurinol for asymptomatic hyperuricemia led to rapid and sustained improvement in lower limb spasticity, allowing marked reduction of antispasmodic therapy. This serendipitous finding suggests a potential therapeutic role of xanthine oxidase inhibition in managing HSP-related spasticity."

Journal • Genetic Disorders • Movement Disorders